Literature DB >> 20083620

Functional effects of glucose transporters in human ventricular myocardium.

Dirk von Lewinski1, Robert Gasser, Peter P Rainer, Marie-Sophie Huber, Bastian Wilhelm, Ulrich Roessl, Tobias Haas, Andrae Wasler, Michael Grimm, Egbert Bisping, Burkert Pieske.   

Abstract

AIMS: Insulin-dependent positive inotropic effects (PIE) are partially Ca(2+) independent. This mechanism is potentially glucose dependent. In contrast to most animal species, human myocardium expresses high levels of sodium-glucose-transporter-1 (SGLT-1) mRNA besides the common glucose-transporters-1 and -4 (GLUT1, GLUT4). METHODS AND
RESULTS: We used ventricular myocardium from 61 end-stage failing human hearts (ischaemic cardiomyopathy, ICM and dilated cardiomyopathy, DCM) and 13 non-failing donor hearts. The effect of insulin on isometric twitch force was examined with or without blocking of PI3-kinase, GLUT4-translocation, or SGLT-1. Substrate-dependent (glucose vs. pyruvate vs. palmitoyl-carnitine) effects were tested in atrial myocardium. mRNA expression of glucose transporters was analysed. Insulin increased developed force by 122 + or - 7.4, 121.7 + or - 2.5, and 134.1 + or - 5.7% in non-failing, DCM, and ICM (P < 0.05 vs. DCM), respectively. Positive inotropic effect was partially blunted by inhibition of PI-3-kinase, GLUT4, or SGLT1. Combined inhibition of PI3-kinase and glucose-transport completely abolished PIE. Positive inotropic effect was significantly stronger in glucose-containing solution compared with pyruvate or palmitoyl-carnitine containing. mRNA expression showed only a tendency towards elevated GLUT4-expression in ICM.
CONCLUSIONS: Positive inotropic effect of insulin is pronounced in ICM, but underlying mechanisms are unaltered. The Ca(2+)-independent PIE of insulin is mediated via glucose-transporters. Together with the Ca(2+)-dependent PI-3-kinase mediated pathway, it is responsible for the entire PIE. Substrate-dependency affirms a glucose-dependent part of the PIE.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20083620     DOI: 10.1093/eurjhf/hfp191

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  18 in total

Review 1.  Energetics and metabolism in the failing heart: important but poorly understood.

Authors:  Aslan T Turer; Craig R Malloy; Christopher B Newgard; Mihai V Podgoreanu
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2010-07       Impact factor: 4.294

2.  Positron emission tomography: An additional prognostic tool in dilated cardiomyopathy?

Authors:  Danilo Neglia
Journal:  J Nucl Cardiol       Date:  2015-08-22       Impact factor: 5.952

3.  Expression of Na+-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences.

Authors:  Ivan Sabolic; Ivana Vrhovac; Daniela Balen Eror; Maria Gerasimova; Michael Rose; Davorka Breljak; Marija Ljubojevic; Hrvoje Brzica; Anne Sebastiani; Serge C Thal; Christoph Sauvant; Helmut Kipp; Volker Vallon; Hermann Koepsell
Journal:  Am J Physiol Cell Physiol       Date:  2012-01-18       Impact factor: 4.249

4.  Dapagliflozin reduces the amplitude of shortening and Ca(2+) transient in ventricular myocytes from streptozotocin-induced diabetic rats.

Authors:  N N Hamouda; V Sydorenko; M A Qureshi; J M Alkaabi; M Oz; F C Howarth
Journal:  Mol Cell Biochem       Date:  2014-10-29       Impact factor: 3.396

5.  The characterization and prognostic significance of right ventricular glucose metabolism in non-ischemic dilated cardiomyopathy.

Authors:  Lei Wang; Xinghong Ma; Liwei Xiang; Minjie Lu; Chaowu Yan; Shihua Zhao; Wei Fang
Journal:  J Nucl Cardiol       Date:  2015-08-08       Impact factor: 5.952

Review 6.  Mitochondrial Ca2+, redox environment and ROS emission in heart failure: Two sides of the same coin?

Authors:  Sonia Cortassa; Magdalena Juhaszova; Miguel A Aon; Dmitry B Zorov; Steven J Sollott
Journal:  J Mol Cell Cardiol       Date:  2020-12-07       Impact factor: 5.000

7.  New insight in understanding the contribution of SGLT1 in cardiac glucose uptake: evidence for a truncated form in mice and humans.

Authors:  Laura Ferté; Alice Marino; Sylvain Battault; Laurent Bultot; Anne Van Steenbergen; Anne Bol; Julien Cumps; Audrey Ginion; Hermann Koepsell; Laure Dumoutier; Louis Hue; Sandrine Horman; Luc Bertrand; Christophe Beauloye
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-01-08       Impact factor: 4.733

8.  Expression of SGLT1 in Human Hearts and Impairment of Cardiac Glucose Uptake by Phlorizin during Ischemia-Reperfusion Injury in Mice.

Authors:  Yusuke Kashiwagi; Tomohisa Nagoshi; Takuya Yoshino; Toshikazu D Tanaka; Keiichi Ito; Tohru Harada; Hiroyuki Takahashi; Masahiro Ikegami; Ryuko Anzawa; Michihiro Yoshimura
Journal:  PLoS One       Date:  2015-06-29       Impact factor: 3.240

9.  Transgenic knockdown of cardiac sodium/glucose cotransporter 1 (SGLT1) attenuates PRKAG2 cardiomyopathy, whereas transgenic overexpression of cardiac SGLT1 causes pathologic hypertrophy and dysfunction in mice.

Authors:  Mohun Ramratnam; Ravi K Sharma; Stephen D'Auria; So Jung Lee; David Wang; Xue Yin N Huang; Ferhaan Ahmad
Journal:  J Am Heart Assoc       Date:  2014-08-04       Impact factor: 5.501

Review 10.  New Antihyperglycemic Drugs and Heart Failure: Synopsis of Basic and Clinical Data.

Authors:  Dirk von Lewinski; Ewald Kolesnik; Markus Wallner; Michael Resl; Harald Sourij
Journal:  Biomed Res Int       Date:  2017-08-15       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.